Signaling Pathway Map

Research Area

  • Inhibitory Selectivity
  • Solubility
Catalog No. Product Name Solubility(25°C)
Water DMSO Alcohol
S1060 Olaparib (AZD2281, Ku-0059436) 0.002 mg/mL 86 mg/mL <1 mg/mL
S1004 Veliparib (ABT-888) <1 mg/mL 17 mg/mL <1 mg/mL
S1098 Rucaparib (AG-014699,PF-01367338) phosphate <1 mg/mL 84 mg/mL <1 mg/mL
S1087 Iniparib (BSI-201) <1 mg/mL 58 mg/mL 28 mg/mL
S7048 Talazoparib (BMN 673) <1 mg/mL 38 mg/mL <1 mg/mL
S9360 4-Hydroxyquinazoline -1 mg/mL 29 mg/mL -1 mg/mL
S8592 Pamiparib (BGB-290) <1 mg/mL 59 mg/mL 45 mg/mL
S2178 AG-14361 <1 mg/mL 12 mg/mL <1 mg/mL
S1132 INO-1001 (3-Aminobenzamide) <1 mg/mL 27 mg/mL 27 mg/mL
S2197 A-966492 <1 mg/mL 64 mg/mL <1 mg/mL
S7300 PJ34 HCl 66 mg/mL 66 mg/mL <1 mg/mL
S2741 Niraparib (MK-4827) <1 mg/mL 64 mg/mL 64 mg/mL
S8038 UPF 1069 <1 mg/mL 56 mg/mL <1 mg/mL
S7029 AZD2461 <1 mg/mL 79 mg/mL 31 mg/mL
S7438 ME0328 <1 mg/mL 64 mg/mL <1 mg/mL
S8370 BGP-15 2HCl 70 mg/mL 70 mg/mL 70 mg/mL
S7625 Niraparib (MK-4827) tosylate <1 mg/mL 98 mg/mL <1 mg/mL
S7730 NU1025 <1 mg/mL 35 mg/mL 6 mg/mL
S7239 G007-LK <1 mg/mL 100 mg/mL <1 mg/mL
S7238 NVP-TNKS656 <1 mg/mL 100 mg/mL 10 mg/mL
S8419 E7449 <1 mg/mL 4 mg/mL <1 mg/mL
S8363 NMS-P118 <1 mg/mL 24 mg/mL 5 mg/mL
S4715 Benzamide <1 mg/mL 24 mg/mL 24 mg/mL
S4710 Picolinamide 24 mg/mL 24 mg/mL 24 mg/mL

Isoform-specific Inhibitors

Catalog No. Information Product Use Citations Product Validations

Olaparib (AZD2281, Ku-0059436)

Olaparib (AZD2281, KU0059436) is a selective inhibitor of PARP1/2 with IC50 of 5 nM/1 nM in cell-free assays, 300-times less effective against tankyrase-1.


Veliparib (ABT-888)

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.


Rucaparib (AG-014699,PF-01367338) phosphate

Rucaparib (AG-014699, PF-01367338) is an inhibitor of PARP with Ki of 1.4 nM for PARP1 in a cell-free assay, also showing binding affinity to eight other PARP domains. Phase 3.


Iniparib (BSI-201)

Iniparib (BSI-201) is a PARP1 inhibitor with demonstrated effectiveness in triple-negative breast cancer (TNBC). Phase 3.


Talazoparib (BMN 673)

Talazoparib (BMN 673) is a novel PARP inhibitor with IC50 of 0.57 nM for PARP1 in a cell-free assay. It is also a potent inhibitor of PARP-2, but does not inhibit PARG and is highly sensitive to PTEN mutation. Phase 3.




Pamiparib (BGB-290)

Pamiparib (BGB-290) is a potent and selective inhibitor of PARP1 and PARP2 with IC50 values of 0.83 and 0.11 nM, respectively in biochemical assays. It shows high selectivity over other PARP enzymes.



AG14361 is a potent inhibitor of PARP1 with Ki of <5 nM in a cell-free assay. It is at least 1000-fold more potent than the benzamides.


INO-1001 (3-Aminobenzamide)

INO-1001 is a potent inhibitor of PARP with IC50 of <50 nM in CHO cells and a mediator of oxidant-induced myocyte dysfunction during reperfusion. Phase 2.



A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with Ki of 1 nM and 1.5 nM, respectively.


PJ34 HCl

PJ34 HCl is the hydrochloride salt of PJ34, which is a PARP inhibitor with EC50 of 20 nM and is equally potent to PARP1/2.


Niraparib (MK-4827)

Niraparib (MK-4827) is a selective inhibitor of PARP1/2 with IC50 of 3.8 nM/2.1 nM, with great activity in cancer cells with mutant BRCA-1 and BRCA-2. It is >330-fold selective against PARP3, V-PARP and Tank1. Phase 3.


UPF 1069

UPF 1069 is a selective PARP2 inhibitor with IC50 of 0.3 μM. It is ~27-fold selective against PARP1.



AZD2461 is a novel PARP inhibitor with low affinity for Pgp than Olaparib. Phase 1.



ME0328 is a potent and selective PARP inhibitor with IC50 of 0.89 μM for PARP3, about 7-fold selectivity over PARP1.


BGP-15 2HCl

BGP-15, is a nicotinic amidoxime derivative with PARP inhibitory activity. It has been demonstrated that BGP-15 protects against ischemia-reperfusion injury.


Niraparib (MK-4827) tosylate

Niraparib (MK-4827) tosylate is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM.



NU1025 is a potent PARP inhibitor with IC50 of 400 nM.



G007-LK is a potent and selective tankyrase inhibitor with IC50 of 46 nM and 25 nM for TNKS1/2, respectively.



NVP-TNKS656 is a highly potent, selective, and orally active tankyrase inhibitor with IC50 of 6 nM for TNKS2, > 300-fold selectivity against PARP1 and PARP2.



E7449 is an orally bioavailable, brain penetrable, small molecule dual inhibitor of PARP1/2 and also inhibits PARP5a/5b, otherwise known as tankyrase1 and 2 (TNKS1/2), important regulators of canonical Wnt/β-catenin signaling. It has IC50 values of 1.0 and 1.2 nM for PARP1 and 2, respectively.



NMS-P118 is a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles, showing 150-fold selectivity for PARP-1 over PARP-2 (Kd 0.009 μM vs 1.39 μM, respectively).



Benzamide, a derivative of benzoic acid, is an inhibitor of poly(ADP-ribose) polymerase with an IC50 of 3.3 μM.



Picolinamide is found to be a strong inhibitor of poly (ADP-ribose) synthetase of nuclei from rat pancreatic islet cells.

Tags: PARP inhibition | PARP cancer | PARP inhibitor cancer | PARP signaling | PARP activity | PARP assay | PARP activity | PARP inhibitor trial | PARP activation | PARP inhibitors clinical trials | FDA approval PARP inhibitor | PARP inhibitor drugs | PARP phosphorylation | PARP inhibitor review